about
Cancer-associated IDH1 mutations produce 2-hydroxyglutarateImmunotherapy response assessment in neuro-oncology: a report of the RANO working groupMonitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patientspH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRICytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients.The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cellsNon-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.Bioluminescent imaging of melanoma in live miceCellular and vaccine therapeutic approaches for gliomasEGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.Radial mobility and cytotoxic function of retroviral replicating vector transduced, non-adherent alloresponsive T lymphocytes.Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway.Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies.2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma modelComparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastomaImmunotherapy for patients with malignant glioma: from theoretical principles to clinical applications.Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brainQuantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen.The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicityEndogenous vaults and bioengineered vault nanoparticles for treatment of glioblastomas: implications for future targeted therapies.An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.Implementing liquid biopsies into clinical decision making for cancer immunotherapy.Immunosensitization with a Bcl-2 small molecule inhibitor.Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression.Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden.Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity.Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination.Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate.
P50
Q24320239-95D91E2A-AA84-42E6-8A5F-A10B46AC2171Q28083009-A6AA8F75-4374-4A91-937A-75A2243F0FE3Q28730798-E641A0B8-923F-4B4A-BD6E-A93EE5C6CB71Q30976860-1CCBACFA-4688-4394-BB2E-ECFC6B62CAA0Q33691858-D948770B-3955-4FC1-B830-C1CC55263E5FQ33928765-CAF99CB4-A8CF-4FF8-AF85-54AF96256306Q34053028-CD0D6DA1-A4DB-47A4-8186-C9A389ED4288Q34077913-2C42B963-C3AA-4CB1-958C-5E4EB43D0701Q34243550-934784C2-E1A7-497F-B668-56E14FFB2892Q34296575-E6058528-E9DA-43F7-BA89-4737BABF90F9Q34518462-4E93B03D-EF88-46B0-83C1-FB3348555179Q34764143-5DD7F949-44B1-4C74-993B-B150D5CE6678Q34976095-C6753751-64A5-4DF8-B16B-6A0EE7FF0EE7Q35162225-7F140A24-DDED-4E04-A0BA-E31325CDD104Q35589288-E0C19E42-F50D-4362-89D4-95483A960178Q36273691-6C225E90-8502-408C-8CAD-C7901B7748E6Q36328206-DD00E504-2EE6-40D1-B001-0C1763EDE2AFQ36401831-EA0E1B9F-D1BB-4867-9A96-F67B20007A77Q36486875-E93EA923-F881-4179-BAC5-0C6379CEF162Q36494531-AE34E402-6440-4C02-B0AB-3E67122A0B90Q36597942-F2BF971F-B382-46F4-A514-DE69F2AC357DQ36618229-013F8EC4-631E-4C21-90EE-C282DEBB1C7CQ36641509-C5D7C5FA-66FB-4A45-8D71-DCD47598E961Q37037932-CCCF1896-0738-476E-9874-F28F63F8BD0BQ37090163-A8C24496-4C4C-4754-87C6-6CD73961DB46Q37271256-9B929A3A-0437-44BF-A487-6EFE82B746F8Q37426386-E4A6BD19-4BFE-4FF0-81C0-EE3B740C0850Q37573880-5ACB4308-4E0F-42F4-942A-BF7B91AF9364Q38022854-A6BA4817-45A7-4AF6-B555-2F90845F63CAQ38926285-C0C17426-3F47-4FF2-B8C0-09AAEC13B4DEQ39003387-26539FF9-05A1-4533-8494-5E9DCE946D78Q39304648-2DA17A9D-C7D8-4EB2-BA25-3FF703B699E8Q39937347-5D5F843C-3FD6-47BB-9742-4B82242E7CC6Q40132461-B45E5DEA-FDD1-42B4-8242-7EFFB9431AEDQ40335222-9B80FE72-E930-41E6-A850-45B320B0C249Q40400501-7C172D42-AD18-4F9F-9A48-2333EF827FF7Q40597268-3650AFF9-A65D-4DE0-8AA8-85C4C7032BEFQ40731894-0ED74172-CA36-4285-90E1-F5B3D3E891CDQ41926372-59A4850A-BEEC-427F-9F96-E9963DA240F2Q42628617-E0DC1B59-CF4B-46D7-BBD2-6F4C5316A408
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Robert M. Prins
@ast
Robert M. Prins
@en
Robert M. Prins
@es
Robert M. Prins
@nl
Robert M. Prins
@sl
type
label
Robert M. Prins
@ast
Robert M. Prins
@en
Robert M. Prins
@es
Robert M. Prins
@nl
Robert M. Prins
@sl
prefLabel
Robert M. Prins
@ast
Robert M. Prins
@en
Robert M. Prins
@es
Robert M. Prins
@nl
Robert M. Prins
@sl
P106
P1153
7101714040
P21
P31
P496
0000-0002-6282-6583